Index
of 2008 Publications
- B Liegl, I Kepten, C Le, M Zhu, GD Demetri, MC Heinrich,
CDM Fletcher, CL Corless, and JA Fletcher.
Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
J Pathol. 2008 May 13. [Epub ahead of print]
Download PDF
PMID:
18623623
- Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ,
Druker BJ, Corless CL, Heinrich MC, Deininger MW.
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Leukemia. 2008 May 29. [Epub ahead of print]
Download PDF
PMID:
18509354
- Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA,
Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van
Oosterom A, Herrmann R, Nikolova Z, McArthur AG; for the Imatinib Target Exploration Consortium Study
B2225.
Phase II, Open-Label Study Evaluating the Activity of Imatinib in
Treating Life-ThreateningMalignancies Known to Be
Associated with Imatinib-SensitiveTyrosine Kinases.
Clin Cancer Res. 2008 May 1;14(9):2717-2725.
Download PDF
PMID:
18451237
- Hodi FS, Friedlander P, Corless CL, Heinrich MC,
Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.
Major response to imatinib mesylate in KIT-mutated melanoma.
J Clin Oncol. 2008 Apr 20;26(12):2046-51.
Download PDF
PMID:
18421059
- Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO,
Heinrich MC, Corless CL, Fire AZ, van de Rijn M.
MicroRNA expression signature of human sarcomas.
Oncogene. 2008 Mar 27;27(14):2015-26. Epub 2007 Oct 8.
Download PDF
PMID:
17922033
- Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, Varma S, Corless CL,
Heinrich MC, Smith KS, Wang Z, Rubin B, Nielsen TO, Seitz RS, Ross DT, West RB, Cleary ML, van de Rijn M.
A Novel Monoclonal Antibody Against DOG1 is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors.
Am J Surg Pathol. 2008 Feb;32(2):210-218.
Download PDF
PMID:
18223323
- Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL,
Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or
metastatic gastrointestinal stromal tumors expressing KIT.
J Clin Oncol. 2008 Feb 1;26(4):620-5.
Download PDF
PMID:
18235121
- Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, Merkelbach-Bruse S, Schildhaus HU,
Steigen SE, Stachura J, Wozniak A, Antonescu C, Daum O, Martin J, Del Muro JG, Miettinen M.
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations:
a multicenter study on 54 cases.
Mod Pathol. 2008 Feb 1; [Epub ahead of print]
Download PDF
PMID:
18246046